Erratum: The effect of iron depletion on chronic hepatitis C virus infection (Hepatology International 10.1007/s12072-008-9076-z);The effect of iron depletion on chronic hepatitis C virus infection

Hepatology International

Volumn 2, Issue 3, 2008, Pages 335-340

  Franchini, Massimo ^a   Targher, Giovanni ^b   Capra, Franco ^b   Montagnana, Martina ^b   Lippi, Giuseppe ^b  

^a OSPEDALE POLICLINICO   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

HCV; IFN; Iron; Phlebotomy; Therapy

Indexed keywords

ALANINE AMINOTRANSFERASE; HFE PROTEIN; INTERFERON; IRON;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIVIRAL ACTIVITY; CELL DEATH; CLINICAL TRIAL; DISEASE ASSOCIATION; DRUG RESPONSE; DRUG TREATMENT FAILURE; EVIDENCE BASED MEDICINE; GENE MUTATION; HEMOCHROMATOSIS; HEPATITIS C; HISTOPATHOLOGY; HUMAN; IRON DEPLETION; IRON OVERLOAD; IRON RESTRICTION; LIVER FIBROSIS; LONG TERM CARE; MONOTHERAPY; PATHOPHYSIOLOGY; PATIENT SAFETY; PHLEBOTOMY; PRIORITY JOURNAL; REVIEW;

EID: 51049084398     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9089-7     Document Type: Erratum

References (63)

1. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345:41-52.
2. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992;102:2108-2113.
3. Bonkowsky HL. Iron as a comorbid factor in chronic viral hepatitis. Am J Gastroenterol 2002;97:1-4.
4. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997;25:759-768.
5. Fujita N, Sugimoto R, Urawa N, Araki J, Mifuji R, Yamamoto M, et al. Hepatic iron accumulation is associated with disease progression and resistance to interferon/ribavirin combination therapy in chronic hepatitis C. J Gastroenterol Hepatol 2007;22:1886-1893.
6. Sherrington CA, Olynyk JK. Iron as a cofactor in chronic hepatitis C infection. Liver 2002;22:187-189.
7. Distante S, Bioro K, Hellum KB, Myrvang B, Berg JP, Skaug K, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002;22:269-275.
8. van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon alpha therapy is influenced by the iron content of the liver. J Hepatol 1994;20:410-415.
9. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995;108:1104-1109.
10. Barton AL, Banner BF, Cable EE, Bonkovsky HL. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am J Clin Pathol 1995;103:419-424.
11. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: Mechanisms of iron induced hepatic fibrogenesis. Semin Liver Dis 2005;25:433-449.
12. Kaito M. Molecular mechanism of iron metabolism and overload in chronic hepatitis C. J Gastroenterol 2007;42:96-99.
13. Kageyama F, Kobayashi Y, Kawasaki T, Toyokuni S, Uchida K, Nakamura H. Successful interferon therapy reverses enhanced hepatic iron accumulation and lipid peroxidation in chronic hepatitis C. Am J Gastroenterol 2000;95:1041-1050.
14. Rigamonti C, Andorno S, Maduli E, Morelli S, Pittau S, Nicosia G, et al. Iron, hepatic stellate cells and fibrosis in chronic hepatitis C. Eur J Clin Invest 2002;32:28-35.
15. Nieto N, Friedman SL, Cederbaum AI. Stimulation and proliferation of primary rat hepatic stellate cells by cytochrome P450 2E1-derived reactive oxygen species. Hepatology 2002;35:62-73.
16. Kakizaki S, Takagi H, Horiguchi N, Toyoda M, Takayama H, Nagamine T, et al. Iron enhances hepatitis C virus replication in cultured human hepatocytes. Liver 2000;20:125-128.
17. Pietrangelo A. Hemochromatosis gene modifies course of hepatitis C viral infection. Gastroenterology 2003;124:1509-1523.
18. Smith BC, Gorve J, Guzail MA, Day CP, Daly AK, Burt AD, et al. Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology 1998;27:1695-1699.
19. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: Relationship with HFE mutations. Gastroenterology 2003;124:318-326.
20. Kazemi-Shirazi L, Datz C, Maier-Dobersberger T, Kaserer K, Hackl F, Polli C, et al. The relation of iron status and hemochromatosis gene mutations in patients with chronic hepatitis C. Gastroenterology 1999;116:127-134.
21. Piperno A, Vergani A, Malosio I, Parma L, Fossati L, Ricci A, et al. Hepatic iron overload in patients with chronic viral hepatitis: Role of HFE gene mutations. Hepatology 1998;28:1105-1109.
22. Bonkovsky HL, Troy N, McNeal K, Banner BF, Sharma A, Obando J, et al. Iron and HFE or TfR1 mutations as comorbid factors for development and progression of chronic hepatitis C. J Hepatol 2002;37:848-854.
23. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, et al. HALT-C Trial Group. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-1451.
24. Valenti L, Pulixi EA, Arosio P, Cremonesi L, Biasiotto G, Dongiovanni P, et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV chronic hepatitis. Haematologica 2007;92:1037-1042.
25. Martinelli AL, Franco RF, Villanova MG, Figueiredo JF, Secaf M, Tavella MH, et al. Are haemochromatosis mutations related to the severity of liver disease in hepatitis C virus infection? Acta Haematol 2000;102:152-156.
26. Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003;38:335-342.
27. Gehrke SG, Stremmel W, Mathes I, Riedel HD, Bents K, Kallinowski B. Hemochromatosis, transferrin receptor gene polymorphisms in chronic hepatitis C: Impact on iron status, liver injury and HCV genotype. J Mol Med 2003;81:780-787.
28. Geier A, Reugels M, Weiskirchen R, Wasmuth HE, Dietrich CG, Siewert E, et al. Common heterozygous hemochromatosis gene mutations are risk factors for inflammation and fibrosis in chronic hepatitis C. Liver Int 2004;24:285-294.
29. Mah YH, Kao JH, Liu CJ, Chen CL, Chen PJ, Lai MY, et al. Prevalence and clinical implications of HFE gene mutations (C282Y and H63D) in patients with chronic hepatitis B and C in Taiwan. Liver Int 2005;25:214-219.
30. Corengia C, Galimberti S, Bovo G, Vergani A, Arosio C, Mariani R, et al. Iron accumulation in chronic hepatitis C: Relation of hepatic iron distribution, HFE genotype, and disease course. Am J Clin Pathol 2005;124:846-853.
31. Thorburn D, Curry G, Spooner R, Spence E, Oien K, Halls D, et al. The role of iron and haemochromatosis gene mutations in the progression of liver disease in chronic hepatitis C. Gut 2002;50:248-252.
32. Negro F, Samii K, Rubbia-Brandt L, Quadri R, Male PJ, Zarski JP, et al. Hemochromatosis gene mutations in chronic hepatitis C patients with and without liver siderosis. J Med Virol 2000;60:21-27.
33. Hohler T, Leininger S, Kohler HH, Schirmacher P, Galle PR. Heterozygosity for the hemochromatosis gene in liver diseases - prevalence and effects on liver histology. Liver 2000;20:482-486.
34. Lal P, Fernandes H, Koneru B, Albanese E, Hameed M. C282Y mutation and hepatic iron status in hepatitis C and cryptogenic cirrhosis. Arch Pathol Lab Med 2000;124:1632-1635.
35. Pirisi M, Scott CA, Avellini C, Toniutto P, Fabris C, Soardo G, et al. Iron deposition and progression of disease in chronic hepatitis C. Role of interface hepatitis, portal inflammation, and HFE missense mutations. Am J Clin Pathol 2000;113:546-554.
36. Ladero JM, Ropero P, Ortega L, Taxonera C, Gonzalez FA, Lopez-Alonso G, et al. HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis. Rev Esp Enferm Dig 2003;95:829-836.
37. Bonkovsky HL. Therapy of hepatitis C: Other options. Hepatology 1997;26:143S-151S.
38. Ioannou GN, Tung BY, Kowdley KV. Iron in hepatitis C: Villain or innocent bystander? Semin Gastroenterol Dis 2002;13:95-108.
39. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994;89:986-988.
40. Hayashi H, Takikawa T, Nishimura N, Yano M. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J Hepatol 1995;22:268-271.
41. Piperno A, Sampietro M, D'Alba R, Roffi L, Fargion S, Parma S, et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996;16:248-254.
42. Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: Biochemical and histological outcome. Dig Liver Dis 2001;33:157-162.
43. Yano M, Hayashi H, Yoshioka K, Kohgo Y, Saito H, Niitsu Y, et al. A significant reduction in serum alanine aminotransferase levels after 3-month iron reduction therapy for chronic hepatitis C: A multicenter, prospective, randomized, controlled trial in Japan. J Gastroenterol 2004;39:570-574.
44. Tanaka N, Horiuchi A, Yamaura T, Komatsu M, Tanaka E, Kiyosawa K. Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: A pilot study. J Gastroenterol 2007;42:49-55.
45. Kawamura Y, Akuta N, Sezaki H, Hosaka T, Someya T, Kobayashi M, et al. Determinants of serum ALT normalization after phlebotomy in patients with chronic hepatitis C infection. J Gatroenterol 2005;40:901-906.
46. Herrera JL. Iron depletion is not effective in inducing a virologic response in patients with chronic hepatitis C who failed to respond to Interferon therapy. Am J Gastroenterol 1999;94:3571-3575.
47. Yano M, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Shiono Y, et al. Long-term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis C. Am J Gastroenterol 2002;97:133-137.
48. Alexander J, Tung BY, Croghan A, Kowdley KV. Effect of iron depletion on serum markers of fibrogenesis, oxidative stress, serum liver enzymes in chronic hepatitis C: Results of a pilot study. Liver Int 2007;27:268-273.
49. Kaito M, Iwasa M, Kobayashi Y, Fujita N, Tanaka H, Gabazza EC, et al. Iron reduction therapy by phlebotomy reduces lipid peroxidation and oxidative stress in patients with chronic hepatitis C. J Gastroenterol 2006;41:921-922.
50. Kimura F, Hayashi H, Yano M, Yoshioka K, Matsumura T, Fukuda T, et al. Additional effect of low iron diet on iron reduction therapy by phlebotomy for chronic hepatitis C. Hepato-gastroenterology 2005;52:563-566.
51. Kato J, Kobune M, Nakamura T, Kuroiwa G, Takada K, Takimoto R, et al. Normalization of elevated hepatic 8-hydroxy-2'-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res 2001;61:8697-8702.
52. Kato J, Miyanishi K, Kobune M, Nakamura T, Takada K, Takimoto R, et al. Long-term phlebotomy with low-iron diet therapy lowers risk of development of hepatocellular carcinoma from chronic hepatitis C. J Gastroenterol 2007;42:830-836.
53. Guyader D, Boucher E, Andre P, Even C, Cottereau J, Bianchi A, et al. A pilot study of iron depletion as adjuvant therapy in chronic hepatitis C patients not responding to interferon. Am J Gastroenterol 1999;94:1696-1699.
54. Tsai NCS, Zuckerman E, Han SH, Goad K, Redeker AG, Fong TL. Effect of iron depletion on long-term response to interferon-alpha in patients with chronic hepatitis C who previously did not respond to interferon therapy. Am J Gastroenterol 1997;92:1831-1834.
55. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-138.
56. Fargion S, Fracanzani AL, Rossini A, Borzio M, Riggio O, Belloni G, et al. Iron reduction and sustained response to interferon-alpha therapy in patients with chronic hepatitis C: Results of an Italian multicenter randomized study. Am J Gastroenterol 2002;97:1204-1210.
57. Carlo C, Daniela P, Giancarlo C. Iron depletion and response to interferon in chronic hepatitis C. Hepato-gastroenterology 2003;50:1467-1471.
58. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Fagiuoli S, Wright HI, et al. Retreatment of hepatitis C interferon non-responders with larger doses of interferon with and without phlebotomy. Hepato-gastroenterology 1996;43:1557-1561.
59. Fong TL, Han SH, Tsai NC, Morgan TR, Mizokami M, Qian D, et al. A pilot randomized, controlled trial of the effect of iron depletion on long-term response to alpha-interferon in patients with chronic hepatitis C. J Hepatol 1998;28:369-374.
60. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, et al. Iron reduction before and during interferon therapy of chronic hepatitis C: Results of a multicenter, randomized, controlled trial. Hepatology 2000;31:730-736.
61. Desai TK, Jamil LH, Balasubramanian M, Koff R, Bonkovsky HL. Phlebotomy improves therapeutic response to interferon in patients with chronic hepatitis C: A meta-analysis of six prospective randomized controlled trials. Dig Dis Sci 2008;53:815-822.
62. Hofer H, Osterreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004;40:1018-1022.
63. Pianko S, McHutchison JG, Gordon SC, Heaton S, Goodman ZD, Patel K, et al. Hepatic iron concentration does not influence response to therapy with interferon plus ribavirin in chronic HCV infection. J Interf Cytokine Res 2002;22:483-489.